Exploring the Latest Developments in Natural Killer (NK) Cell-Based Therapies for Diffuse Intrinsic Pontine Glioma (DIPG)

Diffuse intrinsic pontine glioma (DIPG) is a pediatric brainstem tumor with a very poor prognosis, characterized by immunosuppressive tumor microenvironment (TME) that limits immune infiltration, including a significant reduction in circulating natural killer (NK) cells. This drop in NK cell levels and activity may promote tumor growth and immune evasion, making NK cells a promising target for immunotherapy. NK cells can attack and eliminate DIPG tumor cells, including glioma stem cells, while counteracting certain immune evasion strategies. Although the DIPG microenvironment and blood-brain barrier present challenges, NK cell-based therapies have shown encouraging tumor control and survival benefits in animal models with promising safety results. Current clinical trials for DIPG mostly focus on chimeric antigen receptor (CAR)-T cells targeting disialoganglioside (GD2) and cluster of differentiation 276 (CD276 or B7-H3) antigens with early signs of success, while NK cell therapies, such as CAR-NK cells, are still in preclinical or early stages, requiring further development. The tumor’s immunosuppressive nature poses challenges that may need combination strategies or immune priming. Despite these obstacles, NK cell-based immunotherapy is an exciting and growing field. Upcoming clinical trials emphasize the potential for NK cell therapies to play a critical role in treating this aggressive pediatric brain cancer.